On 8 June 2004, orphan designation (EU/3/04/201) was granted by the European Commission to Ark Therapeutics Limited, United Kingdom, for vascular endothelial growth factor-D gene in an adenoviral vector for use with a collagen collar for the prevention of stenosis in synthetic grafts used in haemodialysis.
In February 2014, Ark Therapeutics Limited changed name to Finvector Vision Therapies Limited.
For a list of the administrative updates to this public summary of opinion, please refer to the PDF document below.
EU/3/04/201: Public summary of positive opinion for orphan designation: Vascular endothelial growth factor-D gene in an adenoviral vector for use with a collagen collar for the prevention of stenosis in synthetic grafts ... (PDF/131.27 KB)
First published: 06/12/2004
Last updated: 03/04/2014
EMA/COMP/260/04 Rev. 4
Vascular endothelial growth factor-D gene in an adenoviral vector for use with a collagen collar
|Disease / condition||
Prevention of stenosis in synthetic grafts used in haemodialysis
|Date of decision||
|Orphan decision number||
Sponsor's contact details
Oakley Road Chinnor
Oxfordshire OX39 4TW
Tel. +44 1844 3556244
Fax +44 1844 353553
For contact details of patients’ organisations whose activities are targeted at rare diseases, see:
- Orphanet, a database containing information on rare diseases, which includes a directory of patients’ organisations registered in Europe;
- European Organisation for Rare Diseases (EURORDIS), a non-governmental alliance of patient organisations and individuals active in the field of rare diseases.